Since 2019, The National Institute of Health and Medical Research (Inserm) has set up a cross-cutting program on GenOmic variability in heaLth and Disease (GOLD) which brings together specialists in the analysis of genomic data with complementary expertise in genetic epidemiology, statistical genetics, bioinformatics and functional genomics.
The teams involved in the GOLD program want to meet the challenge of understanding the role played by genes in the development and progression of diseases. For that, they develop new statistical methods to model the role played by genes in complex phenotypes. To test these methods on real data, a project entitled “Method developments for the genetic analysis of complex traits” was submitted to UKBiobank and access to UKBiobank genetic and phenotypic data was obtained in January 2021 (application reference 59366)
Why the GOLD-UKBB research?
The development of high throughput sequencing technologies has opened-up new possibilities to sequence the human genome and identify all genetic variants in individual genomes. These variants are numerous, reaching a few millions when comparing two human genomes. Indeed, if there is only on average 0.1% sequence differences between the genomes of two individuals, at the scale of a 3 billion base pair genome, this represents ~3 million genetic variants. A majority of these variants are neutral with no impact on individual phenotype but some of them could impair individual health and lead to disease. Identifying these variants and the genes that carry them will help to understand why and how diseases occur and to better prevent and treat them. This is at the foundation of a new medicine, referred to as "genomic medicine" that takes into account patient genomes for a better diagnostic and treatment of diseases.To achieve this objective however, powerful and innovative methods are lacking to integrate longitudinal phenotype information into genetic analyses. The aim of this project is to develop such methods and train them on real datasets.
What will GOLD-UKBB research consist of?
We will develop innovative strategies and methods to analyse genetic data and link the variations observed in individual genomes to differences observed between individuals on different phenotypes that can either be binary phenotypes (affected / non affected by a given disease) or quantitative phenotypes (such as BMI or other measurable traits). The research is primary methodological and not focus on a particular disease or phenotype. The UKBioBank data would be used in different manners. First to generate some realistic synthetic data on which to train the methods and evaluate their statistical properties. These synthetic data will mimic the patterns observed in the real data but some known genetic effects will be added in order to determine how the proposed methods recover these effects. Second, when the methods will be calibrated, they will be applied on the UKBioBank data to determine if some known or novel genetic effects could be detected through a data mining approach. Results will then need to be confirmed on other datasets and/or through experimental validation.
Regulatory information’s about GOLD-UKBB research
Who is the data controller?
Inserm
The legal basis for processing is public interest mission
Data provided by UKBB (source) are analysed by Inserm (data recipient). Only declared investigators (see list below) will have access to this data.
Only genetic (genotyping, exome sequencing and some (50) whole genome sequencing data) and phenotypic data are requested (no biological samples or imaging data).
The GOLD-UKBB research duration is 36 months.
The UKBB data retention period by Inserm is 3 years.
The GOLD-UKBB research has been assessed by an independent ethics committee (IEC), Comité d’évaluation éthique de l’Inserm.
Who to contact?
For more information and to exercise lawful rights (to be informed, of access, of object, to request rectification and erasure), volunteers can contact UKBB, at any time, by the following means:
By writing to UK Biobank at:
1-2 Spectrum Way
Adswood
Stockport
SK3 0SA
Volunteers can also contact the UK Biobank Data Protection Officer (DPO), at any time, by:
By post to :
The Data Protection Officer
UK Biobank Units
1-2 Spectrum Way
Adswood
Stockport
SK3 0SA
Volunteers have the right to contact, at any time, the UK data protection authority - Information Commissioner's Office ("ICO") - if they have any concerns about UK Biobank’s use of personal data and/or UK Biobank’s approach to data protection and the UK GDPR.
All of this information, and more, is available on the UKBB webpage:
The DPOs of Inserm and UKBB will be able to exchange views throughout the duration of the research GOLD-UKBB to respond to requests from volunteers.
The GOLD-UKBB research is carried out in compliance with the General Data Protection Regulation (GDPR) and the regulations of French data protection authority (Cnil).
The list of investigators (in alphabetical order) declared on GOLD-UKBB research
Nom | Prénom | Affiliation |
Béroud | Christophe | UMR1251 Marseille |
Cristofari | Gaël | UMR1081 Nice |
Delahaye Duriez | Andrée | UMR1141 Paris |
Derouin | Margot | UMR1141 Paris |
Génin | Emmanuelle | UMR1078 Brest |
Herzig | Anthony | UMR1078 Brest |
Lanciano | Sophie | UMR1081 Nice |
Leutenegger | Anne-Louise | UMR1141 Paris |
Pratella | David | UMR1081 Nice |
Ludwig | Thomas | UMR1078 Brest |
Marenne | Gaëlle | UMR1078 Brest |
Morange | Pierre-Emmanuel | UMR1263 Marseille |
Perdry | Hervé | UMR1018 Paris |
Saha | Saswati | UMR1090 Marseille |
Salgado | David | UAR 3601 (UMS) – IFB Marseille |
Trégouet | David-Alexandre | UMR1219 Bordeaux |
List updated on 02/22/2022